Zentalis Secures $245.9M Cash Runway, Completes DENALI Part 2a Enrollment
Zentalis Pharmaceuticals completed enrollment in DENALI Part 2a and plans a dose confirmation readout by year-end 2026 while initiating the Phase 3 ASPENOVA trial in the first half of 2026 and advancing the MUIR Part 2 ovarian cancer study. As of December 31, 2025, it held $245.9 million in cash and equivalents, funding operations into late 2027.
1. Pipeline Progress
Zentalis completed enrollment in the Phase 2 DENALI Part 2a trial targeting Cyclin E1-positive platinum-resistant ovarian cancer and expects dose confirmation in 1H 2026 with topline readout by year-end 2026. The company also aligned with regulators on the Phase 3 ASPENOVA confirmatory trial design, set to start in 1H 2026, and is evaluating azenosertib plus bevacizumab as maintenance therapy in the MUIR Part 2 study.
2. Financial Position
As of December 31, 2025, Zentalis held $245.9 million in cash, cash equivalents and marketable securities, providing a runway into late 2027. Research and development expenses fell to $107.3 million in 2025 from $167.8 million in 2024, driven by lower clinical, lab services, drug manufacturing and personnel costs.
3. 2026 Outlook
Key milestones include DENALI dose confirmation in the first half of 2026, initiation of the ASPENOVA Phase 3 trial in H1 2026, and DENALI Part 2 topline results by year-end. Successful readouts could support accelerated approval of azenosertib for Cyclin E1-positive PROC.